뒤로
Vincerx Pharma Inc(VINC) 가격
VINC 주가 차트
VINC 수입
Vincerx Pharma Inc
$0.01
0%
$0
종가: Jan 16, 16:00:00 GMT-5
$0.01
0%
$0
애프터마켓: Jan 16, 20:00:00 GMT-5
최신 수익 결과: Q4 '24
보고됨: 2025-03-27
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
VINC의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Vincerx Pharma Inc VINC의 지난 분기 매출 실적은 어땠나요?
Vincerx Pharma Inc의 매출 추정치는 얼마인가요?
Vincerx Pharma Inc의 수익 품질 점수는 얼마인가요?
Vincerx Pharma Inc는 언제 수익을 보고하나요?
Vincerx Pharma Inc의 예상 수익은 얼마인가요?
Vincerx Pharma Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0.013
시가
$0.0053
일일 범위
$0.0053 - $0.013
52주 범위
$0.001 - $3.04
거래량
22
평균 거래량
9.1K
EPS(TTM)
-19.45
배당수익률
--
시가총액
$67.9K
VINC란 무엇인가요?
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. The company is headquartered in Palo Alto, California and currently employs 12 full-time employees. The company went IPO on 2020-03-10. The firm is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. The company has a next generation bioconjugation platform, called VersAptx. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (positive transcription elongation factor beta (P-TEFb)/CDK9 inhibitor). Its VIP943 is developed using its VersAptx platform and combines an anti-CD123 antibody, a novel legumain-cleavable linker and a kinesin spindle protein inhibitor payload enhanced with CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.